Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, Inc. (Nasdaq: AMRS) will release its financial results for the second quarter ended June 30, 2021, on August 5, 2021. Ahead of market opening, the company will also host a conference call at 6:00 a.m. PT (9:00 a.m. ET) to discuss the results and provide a business update, featuring executives John Melo, Han Kieftenbeld, and Eduardo Alvarez. The call will be accessible via Amyris' Investor Relations website and available for 90 days post-event.
Amyris, Inc. (Nasdaq: AMRS) announced an exclusive license with Nant Africa, LLC for its RNA COVID vaccine developed with the Infectious Disease Research Institute. The agreement could yield millions in upfront and milestone payments, along with long-term royalties. It includes funding for human clinical trials and aims for vaccine production in South Africa by year-end. The RNA technology shows comparable immunity to authorized vaccines and has lower production costs. This represents Amyris' first major pharmaceutical license, enhancing its commitment to accessible healthcare.
Amyris, Inc. (Nasdaq: AMRS) has partnered with UNCF and 10,000 Degrees to establish a $180,000 scholarship fund aimed at supporting Black and African American students in STEM, business, and marketing. The initiative underscores Amyris' commitment to diversity and education. UNCF, with over $5 billion raised, has assisted more than 500,000 students, while 10,000 Degrees has provided over $80 million in scholarships. This collaboration seeks to enhance access to education and foster a diverse workforce in the biotech sector.
Amyris, a leader in synthetic biotechnology, will have CEO John Melo present at the Jefferies Virtual Consumer Conference on June 23, 2021, at 3:15 pm ET. The event will be streamed live, with a replay available on the company’s Investor Relations page. Amyris is known for its sustainable ingredients in the Clean Health and Beauty sectors and offers popular brands such as Biossance and Pipette. The company prides itself on a No Compromise® promise of clean ingredients.
Amyris, Inc. (Nasdaq: AMRS) has announced a binding term sheet for the acquisition of clean wellness company OLIKA Inc., aiming to boost its growth in the clean health and beauty sector. OLIKA, known for its sustainable hand sanitizers, aligns with Amyris's commitment to transparent and effective ingredients. Alastair Dorward, a seasoned brand leader, will join Amyris as Chief Brand Officer. This acquisition strengthens Amyris's consumer brand portfolio, including Pipette, and is positioned to enhance their market leadership in sanitizing and household cleaning products.
Amyris (Nasdaq: AMRS), a leader in synthetic biotechnology for the Clean Health and Beauty markets, will have CEO John Melo participate in a virtual fireside chat at the Morgan Stanley 6th Annual Sustainable Futures Conference on June 9, 2021, at 3:30 pm ET. A live webcast and replay will be available on their Investor Relations page. Amyris focuses on sustainable ingredients and operates brands like Biossance and Pipette, reaching over 200 million consumers.
Amyris, Inc. (Nasdaq: AMRS), a synthetic biotechnology leader, announced it has secured commitments for over 10,000 new retail doors across North America, including major retailers like Sephora and CVS. This expansion of its clean beauty brands is expected to enhance sales over the next two quarters. The company's innovative Lab-to-Market biotechnology platform positions it uniquely within the clean health and beauty market, aiming to meet increasing consumer demand for sustainable products. John Melo emphasizes the strong market demand for high-quality, sustainable consumer products.
Amyris, Inc. (Nasdaq: AMRS) announced its participation in a fireside chat at the Morgan Stanley Global Consumer Ingredients Day on May 18, 2021, at 10:45 am ET. This virtual event will showcase the company's advancements in sustainable ingredients for the Clean Health & Beauty markets.
A live webcast and replay will be accessible on Amyris' Investor Relations website, offering insights into their technology and product offerings, including notable brands like Biossance and Pipette. For more details, visit investors.amyris.com.
Amyris reported a record $177 million in total revenue for Q1 2021, driven by a 37% increase in underlying revenue and significant contributions from strategic ingredient transactions. Product revenue surged 47% to $28 million, bolstered by a 73% rise in consumer sales. Adjusted EBITDA reached $103 million, showing a massive improvement year-over-year. The company is on track to achieve full-year revenue of approximately $400 million and expects positive adjusted EBITDA for the year, alongside reduced debt levels.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
